biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 24-hour CEO

<< Previous

Bullboard Posts

Next >>

Comment by Aarcoron Dec 14, 2020 4:17pm

167 Views

Post# 32102305

RE:RE:RE:RE:24-hour CEO

Ok, so just to be clear, you have no more information than any other shareholder, and are playing the "what if" BTI management isn't actually incompetent game. Got it, thanks.

Denali is worth $10B USD today. The mice say xb3 is better. What if BTI's CEO worked full-time and got 10 major deals next year and took 001 to the clinic ? BTI would be worth $10B next year. We would all be rich. Hooray! Am I doing it right ?

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments